论文部分内容阅读
目的探讨吉西他滨联合多西紫杉醇新辅助化疗方案在晚期非小细胞肺癌中的应用观察。方法 2008年2月至2010年10月符合入选标准晚期非小细胞肺癌患者134例分为GT组64例,NP组70例,观察两组病例临床疗效、分期下调率及毒性反应。结果 GT组总有效率46.87%,NP组总有效率51.42%,两组比较,差异无统计学意义(P>0.05)。两组不良反应中白细胞减少、血小板减少、发生率进行比较,差异无统计学意义(P>0.05)。两组病例消化系统不良反应恶心呕吐症状进行比较,差异有统计学意义(P<0.05)。结论吉西他滨联合多西紫杉醇新辅助化疗方案与含铂方案相比近期疗效,总有效率相似,胃肠道反应轻微易于被患者所接受。
Objective To investigate the application of gemcitabine combined with docetaxel neoadjuvant chemotherapy in advanced non-small cell lung cancer. Methods From February 2008 to October 2010, 134 patients with advanced non-small cell lung cancer who met the inclusion criteria were divided into two groups: 64 cases in the GT group and 70 cases in the NP group. The clinical efficacy, the down-regulation rate and the toxicity of the two groups were observed. Results The total effective rate was 46.87% in GT group and 51.42% in NP group. There was no significant difference between the two groups (P> 0.05). Two groups of adverse reactions leukopenia, thrombocytopenia, the incidence was compared, the difference was not statistically significant (P> 0.05). Two groups of patients with digestive system adverse reactions nausea and vomiting were compared, the difference was statistically significant (P <0.05). Conclusion The combination of gemcitabine plus docetaxel neoadjuvant chemotherapy regimen has similar efficacy and platinum-containing regimens with similar efficacy and mild gastrointestinal reactions.